RT-1999 / Raya Therap - LARVOL DELTA

Raya Therapeutic Announces Oral Presentation and Poster at International Symposium on ALS/MND in Montreal December 6-8 (EIN News) - "Raya Therapeutic Inc...announces the presentation of the Phase 2 ROCK-ALS study data for its lead compound, fasudil (RT1968) for the treatment of Amyotrophic Lateral Sclerosis (ALS) by Dr. Paul Lingor (Principal Investigator) on Friday, December 6th at the 35th International Symposium on ALS/MND in Montreal...The company would also like to announce a poster presentation...entitled: 'The novel combination of 2 clinical-stage molecules demonstrates a beneficial effect in preclinical models of ALS.' Raya is also developing 2 novel small molecules, RT1972 and RT1999, each of which have neuroprotective effects in ALS preclinical models...Raya believes that this is the first presentation of a combination of two new chemical entities across multiple preclinical models of ALS."

P2 data • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders